Appointment dossier — Intracranial Sarcoma
Bring this to your appointment. It summarizes what published studies report — it is not medical advice and does not say anything works. Decisions are yours and your care team’s.
Compounds studied in Intracranial Sarcoma
- Carboplatin — Human evidence · 2 positive · PMID 37508972, 26588458
- Etoposide — Human evidence · 2 positive · PMID 37508972, 26588458
- Ifosfamide — Human evidence · 2 positive · PMID 37508972, 26588458
“Positive” means a study reported a positive result — most are early lab/animal work that may not translate to people.
Open recruiting trials (18)
- NCT05019703 · Phase 2 — Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study (United States)
- NCT07261631 · Phase 1 — Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors (Canada)
- NCT04354064 — Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors (United States)
- NCT05961761 · Phase 2 — Propranolol and Pembrolizumab in Advanced Soft Tissue Sarcoma Patients (Denmark)
- NCT04072042 · Phase 2 — BIOmarker Driven Trial of VEGFR2 Inhibitor in Advanced or Metastatic Sarcoma (China)
- NCT07650656 · Phase 2 — Fluorescence-Guided Surgical Resection for Reducing Unexpected Positive Margins in Patients With Sarcoma, SarcoSIGHT Trial (United States)
- NCT07169344 · Phase 2 — Hypofractionated, 3-week, Preoperative Proton or X-ray Radiotherapy for Patients With Localized Soft Tissue Sarcoma (Norway)
- NCT06436612 · Phase 2 — Study of Magnetic Resonance Image and Computed Tomography-Guided Stereotactic Body Radiation Therapy for Abdominopelvic Sarcomas (MARS Trial) (United States)
- NCT07321912 · Phase 2 — Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma (United States)
- NCT06709495 · Phase 1 / Phase 2 — Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas (United States)
- NCT05839275 · Phase 1 / Phase 2 — The Combination of Radiotherapy，Surufatinib and Sintilimab in High-Risk Localized Soft Tissue Sarcoma (China)
- NCT07014137 · Phase 2 — A Trial of ABSK043, an Oral PD-L1 Inhibitor, in Patients With Angiogenic Sarcomas (Canada)
- NCT04902443 · Phase 1 — Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV (United States)
- NCT06156410 · Phase 1 — Cabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas (United States)
- NCT06889766 · Phase 1 — NY-ESO-1-redirected T Cells in Patients With Advanced Melanoma and Sarcoma (Switzerland)
- NCT07048249 · Early Phase 1 — Single Arm Romiplostim to Prevent CIT (United States)
- NCT07188532 — Biologically-Adapted, Dose-Escalated Radiotherapy for the Treatment of Ewing Sarcoma, BEAR Trial (United States)
- NCT07609329 — Preoperative Immunonutrition in Patients With Bone and Soft Tissue Sarcomas (Czechia)
Most-relevant first: trials that name Intracranial Sarcoma, then broader trials you may still qualify for. Eligibility is decided by each trial's team — bring these NCT numbers to your appointment.
Financial help to look into
- PAN Foundation — Copay assistance funds by diagnosis (funds open and close as money allows). https://www.panfoundation.org/
- HealthWell Foundation — Copay and premium assistance funds by disease. https://www.healthwellfoundation.org/
- CancerCare — financial assistance — Limited grants plus free financial counseling. https://www.cancercare.org/financial
- Family Reach — Help with everyday living costs (rent, transport, food) during treatment. https://familyreach.org/
- NeedyMeds — Searchable directory of drug patient-assistance and discount programs. https://www.needymeds.org/
For each medicine above, search manufacturer and nonprofit programs at medicineassistancetool.org.
Questions to ask your oncologist
- I've read that Carboplatin has been studied in people for Intracranial Sarcoma — what's the evidence, and is it an option or available in a trial for me?
- I've read that Etoposide has been studied in people for Intracranial Sarcoma — what's the evidence, and is it an option or available in a trial for me?
- I've read that Ifosfamide has been studied in people for Intracranial Sarcoma — what's the evidence, and is it an option or available in a trial for me?
- Of the open trials I found (for example NCT05019703), am I eligible for any — here or at a larger cancer center?
- What is my exact diagnosis — the type, subtype, stage, and grade?
- Has my tumor had molecular or genomic testing (e.g. next-generation sequencing), and what did it find?
- Should I have inherited (germline) genetic testing, and could it affect my treatment or my family?
- What is the goal of treatment for me — cure, long-term control, or comfort?
- What are all of my standard treatment options, and what does each one involve?
- What is the realistic benefit of each option, in actual numbers?
- What are the most common and the most serious side effects, and how are they managed?
- How will we know if treatment is working, and how often will I be scanned or tested?
- If the first treatment doesn't work, what are the next options?
- Are there gentler options if I want to prioritize quality of life?
- Am I eligible for any clinical trials — here or at a larger/academic cancer center?
- Is my case reviewed by a multidisciplinary tumor board?
- Would a second opinion at a center that treats my cancer often be worthwhile?
- Could any of my prescriptions, over-the-counter drugs, or supplements interfere with treatment?
- Which symptoms are emergencies, and who do I call after hours?
- Should I see palliative or supportive care alongside my treatment?
- How will treatment affect my daily life, work, and (if it matters to me) fertility?
- What can I safely do myself — diet and activity — and is anything I'm taking risky?